These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26411431)

  • 1. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.
    Katayama Y; Ozawa T; Shiono N; Masuhara H; Fujii T; Watanabe Y
    Gen Thorac Cardiovasc Surg; 2017 Nov; 65(11):622-626. PubMed ID: 28647800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term administration of tolvaptan after open heart surgery.
    Matsuyama K; Koizumi N; Nishibe T; Iwasaki T; Iwahasi T; Toguchi K; Takahashi S; Iwahori A; Maruno K; Ogino H
    Int J Cardiol; 2016 Oct; 220():192-5. PubMed ID: 27379922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Suehiro Y; Hosono M; Shibata T; Sasaki Y; Hirai H; Nakahira A; Kubota Y; Kaku D; Suehiro S
    Osaka City Med J; 2016 Dec; 62(2):111-119. PubMed ID: 30721586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.
    Kato TS; Ono S; Kajimoto K; Kuwaki K; Yamamoto T; Amano A
    J Cardiothorac Surg; 2015 Nov; 10():143. PubMed ID: 26525900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
    Fukunami M; Matsuzaki M; Hori M; Izumi T;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S47-56. PubMed ID: 22120093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.
    Yamada M; Nishi H; Sekiya N; Horikawa K; Takahashi T; Sawa Y
    Surg Today; 2017 Apr; 47(4):498-505. PubMed ID: 27553014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery?　- Results of a Single-Center Randomized Controlled Study.
    Kishimoto Y; Nakamura Y; Harada S; Onohara T; Kishimoto S; Kurashiki T; Fujiwara Y; Nishimura M
    Circ J; 2018 Mar; 82(4):999-1007. PubMed ID: 29467353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.
    Kido T; Nishi H; Toda K; Ueno T; Kuratani T; Sakaki M; Takahashi T; Sawa Y
    Gen Thorac Cardiovasc Surg; 2017 Feb; 65(2):110-116. PubMed ID: 27645146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advent of New perioperative care for fluid management after cardiovascular surgery: A review of current evidence.
    Nishi H
    J Cardiol; 2020 Jun; 75(6):606-613. PubMed ID: 31980355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III clinical pharmacology study of tolvaptan.
    Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: new treatment with Tolvaptan for heart failure after cardiac surgery.
    Sezai A; Iida M; Yoshitake I; Osaka S; Hata H; Shiono M
    Heart Surg Forum; 2014 Aug; 17(4):E198-200. PubMed ID: 25179972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.
    Tanaka A; Katsuno T; Ozaki T; Sakata F; Kato N; Suzuki Y; Kosugi T; Kato S; Tsuboi N; Sato W; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
    Acta Cardiol; 2015 Apr; 70(2):217-23. PubMed ID: 26148383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.